文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-PSMA-617治疗晚期前列腺癌中克隆性造血的临床影响与动态变化

Clinical Impact and Dynamics of Clonal Hematopoiesis with 177Lu-PSMA-617 Therapy in Advanced Prostate Cancer.
PubMed 文献 · J Nucl Med · 2026-10-01

克隆性造血与总生存无显著关联,但血液学毒性有增加趋势,且DNA损伤修复相关克隆在治疗中常见扩增或新发。

要点

  • 接受177Lu-PSMA-617治疗的患者中克隆性造血患病率高达66%。
  • 克隆性造血与总生存无显著差异,但血液学毒性和生长因子支持需求有增加趋势。
  • 治疗期间及治疗后DNA损伤修复相关克隆扩增或新发非常常见。

核心结论

  • 在转移性去势抵抗性前列腺癌患者中,接受177Lu-PSMA-617治疗时克隆性造血高度流行,并倾向于导致更严重的血液学毒性。
  • DNA损伤修复相关克隆性造血克隆在177Lu-PSMA-617治疗期间和治疗后扩增或新发非常常见。

研究设计与样本

  • 对2022年至2023年在本机构接受至少4周期177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者进行外周血DNA的21个克隆性造血相关基因靶向下一代测序。

主要发现

  • 33例(66%)患者检测到至少1种克隆性造血变异,最常见突变为TET2(n=16)、PPM1D(n=15)和DNMT3A(n=6)。
  • 有无克隆性造血患者的总生存相似(12个月总生存率92% vs. 80%;风险比0.89;95%CI 0.3-2.68)。
  • 克隆性造血患者血液学毒性有增加趋势,生长因子支持需求更高(12% vs. 0%)。
  • 在有连续样本的患者中,大多数检测到新克隆出现或已有克隆性造血变异扩增,尤其是PPM1D和TP53突变克隆。

临床怎么用

  • 对接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,可关注克隆性造血状态以评估血液学毒性风险。
  • 治疗期间及治疗后应监测克隆性造血克隆的动态变化,尤其是DNA损伤修复相关克隆。

局限性

  • 样本量小且随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence, clinical impact, and clonal dynamics of clonal hematopoiesis (CH) in patients receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration-resistant prostate cancer (mCRPC) are unknown. Methods: Targeted next-generation sequencing of 21 genes recurrently mutated in CH was performed on DNA extracted from the peripheral blood of patients who received at least 4 cycles of LuPSMA for mCRPC at our institution between 2022 and 2023. Pathogenic somatic mutations with a variant allele fraction of at least 1% were identified using a standardized pipeline. Clinical outcomes pertaining to efficacy (overall survival [OS], measured from date of planned cycle 5) and hematologic toxicity of LuPSMA were collected from the electronic medical record. Results: Fifty patients treated with LuPSMA were eligible, with a median follow-up of 23 mo. At least 1 CH variant was detected in 33 patients (66%). The most common mutations were TET2 (n = 16), PPM1D (n = 15), and DNMT3A (n = 6). OS was similar in patients with or without CH (12-mo OS, 92% vs. 80%; hazard ratio, 0.89; 95% CI, 0.3-2.68). There was a trend toward greater hematologic toxicity in patients with CH, with a greater need for growth factor support (12% vs. 0%). In patients with serial samples available, the emergence of new clones or expansion of preexisting CH variants was detected in most patients, particularly with PPM1D and TP53-mutant clones. The key limitation was the small sample size and short follow-up. Conclusion: CH was highly prevalent and tended to lead to greater hematologic toxicity in patients with mCRPC receiving LuPSMA. Expansion or emergence of DNA damage repair CH clones was very common during and after LuPSMA therapy. Further study of the impact of CH on radiopharmaceutical therapy, particularly when used in earlier prostate cancer disease settings, is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ravi P, Zhong C, Perez KJ, et al. Clinical Impact and Dynamics of Clonal Hematopoiesis with 177Lu-PSMA-617 Therapy in Advanced Prostate Cancer. J Nucl Med. 2026. PMID: 42463292. doi:10.2967/jnumed.126.272125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。